Platinum-Resistant Ovarian Cancer Treatment Market Gains Traction During the Forecast Period (2020-2034) with Advancements in Biomarker-Driven and Targeted Therapies | DelveInsight

The platinum-resistant ovarian cancer market is anticipated to witness substantial growth owing to the increasing burden of recurrent ovarian cancer, rising resistance to platinum-based chemotherapy, and the growing demand for effective second- and later-line treatment options. The emergence of precision oncology approaches, antibody-drug conjugates, targeted agents, and immunotherapy combinations is reshaping the treatment landscape. Emerging therapies such as Relacorilant [Corcept Therapeutics], Catequentinib/Anlotinib [Advenchen Laboratories], Ubamatamab [Regeneron Pharmaceuticals], Afuresertib [Laekna Therapeutics], and others are expected to strengthen the platinum-resistant ovarian cancer market during the forecast period.

DelveInsight's Platinum-Resistant Ovarian Cancer Market Insights report provides a detailed evaluation of existing treatment practices, emerging therapeutic candidates, competitive landscape, market share of individual therapies, and market forecasts from 2020 to 2034 across the 7MM, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Request for free sample report now: https://www.delveinsight.com/sample-request/platinum-resistant-ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Platinum-Resistant Ovarian Cancer Market Report
• The platinum-resistant ovarian cancer market size across the 7MM is projected to expand considerably through 2034.
• Among the major markets, the United States represented the largest platinum-resistant ovarian cancer market size in 2024 compared to the EU4, the UK, and Japan.
• Across the 7MM, ovarian cancer incidence remained significant, with the United States accounting for nearly 20,000 reported cases.
• Increasing relapse rates following platinum-based chemotherapy continue to create a high unmet medical need, supporting demand for innovative therapies targeting platinum-resistant disease.
• Major pharmaceutical and biotechnology companies, including Corcept Therapeutics, Advenchen Laboratories, Regeneron Pharmaceuticals, Laekna Therapeutics, and others, are actively advancing novel therapies for platinum-resistant ovarian cancer.
• Key pipeline therapies currently under investigation include Relacorilant (CORT125134), Catequentinib (Anlotinib), Ubamatamab (REGN4018) ± Cemiplimab, Afuresertib (LAE002) + Paclitaxel, and several additional candidates anticipated to enter the market during the forecast timeline.

Key Drivers Accelerating the Platinum-Resistant Ovarian Cancer Market
Increasing Incidence of Ovarian Cancer
The growing prevalence and incidence of ovarian cancer are contributing significantly to market growth. In 2024, approximately 61,000 incident ovarian cancer cases were reported across the 7MM. Since a substantial proportion of patients eventually relapse following first-line therapy, demand for advanced treatment options for platinum-resistant disease is expected to rise steadily.

Growing Adoption of Biomarker-Based Therapies
The emergence of folate receptor alpha (FRα) as an important predictive biomarker has accelerated the development of precision-based therapies in platinum-resistant ovarian cancer. The success of ELAHERE (mirvetuximab soravtansine) has highlighted the therapeutic potential of targeted antibody-drug conjugates capable of selectively attacking FRα-overexpressing ovarian tumors while minimizing off-target toxicities.

Expansion of the Emerging Therapy Pipeline
The clinical pipeline for platinum-resistant ovarian cancer continues to strengthen with several companies progressing innovative therapies. Drug developers such as Corcept Therapeutics, Advenchen Laboratories, Regeneron Pharmaceuticals, and Laekna Therapeutics are advancing novel candidates designed to overcome resistance mechanisms and improve clinical outcomes in recurrent disease settings.

Request for free sample report now: https://www.delveinsight.com/sample-request/platinum-resistant-ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Platinum-Resistant Ovarian Cancer Market Analysis
The therapeutic landscape for platinum-resistant ovarian cancer remains complex due to limited efficacy associated with conventional chemotherapy in recurrent settings. As a result, pharmaceutical innovation is increasingly focused on targeted approaches, combination regimens, and biomarker-guided therapies.

A major development in the market occurred with the FDA approval of ELAHERE for FRα-positive platinum-resistant ovarian cancer, demonstrating meaningful improvements in progression-free survival and overall survival compared to standard chemotherapy. This milestone reinforced the growing role of molecular diagnostics in treatment selection and personalized oncology care.

In parallel, several investigational therapies are showing encouraging clinical activity. Corcept Therapeutics' relacorilant, when combined with nab-paclitaxel, has demonstrated promising efficacy in resistant ovarian cancer populations. Advenchen Laboratories' catequentinib (anlotinib), a multitarget tyrosine kinase inhibitor, is also being evaluated for recurrent and resistant disease.
Immunotherapy-based approaches are gaining attention as well. Regeneron Pharmaceuticals' ubamatamab (REGN4018), a MUC16 x CD3 bispecific antibody, is under investigation with or without cemiplimab to enhance antitumor immune responses. Additionally, Laekna Therapeutics' afuresertib (LAE002), an AKT inhibitor combined with paclitaxel, reflects the broader industry trend toward multi-pathway inhibition strategies in platinum-resistant ovarian cancer management.

Platinum-Resistant Ovarian Cancer Competitive Landscape
The competitive environment for platinum-resistant ovarian cancer is evolving rapidly, supported by robust clinical development activities across multiple therapeutic classes.
Corcept Therapeutics' Relacorilant is a selective glucocorticoid receptor modulator designed to specifically target cortisol signaling pathways without interacting with other hormone receptors. The therapy is being explored in ovarian cancer and several additional malignancies, including adrenal and prostate cancers, as well as endocrine disorders such as Cushing's syndrome.

Advenchen Laboratories' Catequentinib (Anlotinib) is an oral receptor tyrosine kinase inhibitor targeting VEGFR, FGFR, PDGFR, c-Kit, and RET pathways. Through simultaneous inhibition of angiogenesis and tumor proliferation pathways, the therapy has demonstrated potential in recurrent ovarian cancer settings and is currently being evaluated in Phase III clinical studies.

In February 2024, Advenchen Laboratories announced completion of dose-limiting toxicity assessments in the Japan run-in cohort of the AL3818-US-002 global Phase III PROC study, allowing the trial to move into the close-out phase.
Regeneron Pharmaceuticals is also advancing ubamatamab (REGN4018), a bispecific T-cell engager targeting MUC16-positive ovarian tumors. The therapy is being investigated both as monotherapy and in combination with cemiplimab to improve immune-mediated tumor destruction in resistant disease populations.

The anticipated introduction of these innovative therapies is expected to significantly transform the platinum-resistant ovarian cancer market over the coming decade. As next-generation targeted therapies and immuno-oncology combinations advance through late-stage development and achieve regulatory approvals, they are likely to redefine standards of care and create substantial commercial opportunities within the oncology market.

Request for free sample report now: https://www.delveinsight.com/sample-request/platinum-resistant-ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Recent Developments in the Platinum-Resistant Ovarian Cancer Market
• In May 2026, Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that the first patient has been dosed in the Phase 3 ASPENOVA clinical trial (NCT07546500, GOG-3147, ENGOT-ov109, APGOT-OV27) evaluating azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
• In April 2026, Qilu Pharmaceutical announced encouraging Phase I clinical trial results for its investigational Claudin 6 (CLDN6)-targeting antibody-drug conjugate (ADC), QLS5132, in patients with advanced platinum-resistant ovarian cancer. The data, presented at the 2026 AACR Annual Meeting, showed an objective response rate of 50% and a disease control rate of 94.4% among evaluable patients.
• In December 2025, AbbVie-sponsored symposium at the ESMO Asia Congress 2025, experts gathered to address platinum resistance in advanced ovarian cancer with Antibody Drug Conjugates (ADCs). The discussion underscored the pressing need to rethink traditional definitions of platinum resistance and explore new strategies to treat one of the most persistent and challenging treatment obstacles so as to improve patient outcomes.
• In July 2025, Corcept Therapeutics announced the submission of a New Drug Application (NDA) to the US FDA for relacorilant for the treatment of patients with platinum-resistant ovarian cancer.
• In April 2025, Mural Oncology disclosed the discontinuation of clinical development activities for nemvaleukin alfa following analysis of data from the Phase II ARTISTRY-6 melanoma trial and the previously reported Phase III ARTISTRY-7 PROC study.
• In March 2025, Sutro Biopharma completed a strategic portfolio review and announced prioritization of its wholly owned next-generation antibody-drug conjugate programs. While development of luveltamab tazevibulin (luvelta) would not continue independently, the company remains open to strategic partnership opportunities.

What is Platinum-Resistant Ovarian Cancer?
Ovarian cancer accounts for nearly 3% of cancers affecting women yet remains among the leading causes of gynecologic cancer-related mortality. The disease often progresses silently with minimal symptoms and limited screening options, resulting in late-stage diagnosis for the majority of patients.

Although platinum-based chemotherapy remains the cornerstone of ovarian cancer treatment, recurrence is highly common. Platinum-resistant ovarian cancer is defined by disease recurrence within six months following completion of platinum-based therapy. This form of the disease presents a major clinical challenge because resistance mechanisms significantly reduce responsiveness to conventional chemotherapy, creating a substantial unmet therapeutic need.

Platinum-Resistant Ovarian Cancer Epidemiology Segmentation
The platinum-resistant ovarian cancer epidemiology section of the report provides detailed insights into historical trends and future patient population forecasts across the 7MM.
Among ovarian cancer subtypes, serous ovarian cancer accounted for the largest proportion of cases throughout the study period. Approximately 80% of patients diagnosed with advanced ovarian cancer and nearly 20% of those with early-stage disease eventually experience recurrence after initial therapy.

The report includes epidemiological forecasts segmented by:
• Total Incident Cases of Ovarian Cancer
• Site-specific Incident Cases of Ovarian Cancer
• Stage-specific Incident Cases of Ovarian Cancer
• Mutation-specific Incident Cases of Ovarian Cancer
• Line-wise Treated Cases of Ovarian Cancer
• Total Incident Cases of Platinum-Resistant Ovarian Cancer

Request for free sample report now: https://www.delveinsight.com/sample-request/platinum-resistant-ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Platinum-Resistant Ovarian Cancer Market Report
• Study Period: 2020-2034
• Coverage: 7MM (US, EU4, UK, Japan)
• Key Companies: Corcept Therapeutics, Advenchen Laboratories, Regeneron Pharmaceuticals, Laekna Therapeutics, and others
• Key Therapies: Relacorilant (CORT125134), Catequentinib (Anlotinib), Ubamatamab (REGN4018) ± Cemiplimab, Afuresertib (LAE002) + Paclitaxel, and others
• Comprehensive assessment of marketed and emerging therapies
• Market dynamics and forecast assumptions
• Competitive intelligence and SWOT analysis
• Analyst perspectives and KOL insights
• Market access and reimbursement analysis
• Evaluation of unmet needs and future treatment opportunities

Table of Contents
1. Platinum-Resistant Ovarian Cancer Market Key Insights
2. Platinum-Resistant Ovarian Cancer Market Report Introduction
3. Executive Summary of PROC
4. Key Events
5. Epidemiology and Market Methodology
6. Market Overview at a Glance
7. Disease Background and Overview
8. Current Treatment Landscape and Guidelines
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Therapies
12. Emerging Therapies
13. 7MM Market Analysis
14. Unmet Needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Bibliography
19. Report Methodology

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.